Background {#s1}
==========

Resistance to tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (*EGFR*) mutated non-small cell lung cancer (NSCLC) is well established to be mediated by histological transformation to SCLC in 3%--14% of cases.[@R1] Similarly, transformation of prostate adenocarcinoma to small cell carcinoma on androgen-deprivation therapy is reported to occur at an incidence of 17% and is associated with poor survival outcomes.[@R4] More recently, reports have emerged regarding SCLC transformation of NSCLC as a resistance mechanism to immune checkpoint inhibitors (ICPIs). However, unlike disease progression on TKIs, repeat tissue biopsies are not universally recommended at the time of NSCLC progression on ICPIs.

Case presentation {#s2}
=================

In our practice, we cared for a patient who had small cell transformation of stage IV poorly differentiated squamous cell carcinoma of the lung after prolonged nivolumab monotherapy ([figure 1](#F1){ref-type="fig"}). She was in her mid-60s with a history of 35 pack-years of smoking at the time of diagnosis of her lung cancer (metastatic to lungs, mediastinal lymph nodes and L1 vertebral body) with no targetable genomic alterations. After a short-lived response to first-line platinum-gemcitabine chemotherapy lasting less than 4 months, she had progression of her disease. She was then switched to nivolumab monotherapy, with sustained partial response for 21 months. On follow-up imaging, she was noted to have bulky mediastinal and right hilar lymphadenopathy; biopsy showed SCLC. Review of the biopsy at initial NSCLC diagnosis did not show any small cell component. Tumor genomic profiling performed at initial diagnosis and following disease progression on nivolumab showed nearly identical results ([table 1](#T1){ref-type="table"}). Treatment with carboplatin/etoposide led to near-complete response, however, lasting for only 10 months. Biopsy of the tumor again confirmed small cell histology. She was treated with concurrent nivolumab and radiotherapy to the chest, though ultimately elected to pursue comfort focused care and died 14 months after the detection of neuroendocrine transformation.

![Case presentation of small cell transformation of non-small cell lung cancer on nivolumab monotherapy, including treatment details, and radiographic and pathological findings. Time on therapy is not drawn to scale. CT, computed tomography; H&E, hematoxylin and eosin; PET, positron emission tomography; Rx, treatment; XRT, radiotherapy.](jitc-2020-000697f01){#F1}

###### 

Summary of clinical and tumor genomic characteristics of patients included in the review

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source                                          Age/sex at NSCLC dx   Smoking status at NSCLC dx   Histology/\                                  Genomic profile of original NSCLC                                                                  Treatment of NSCLC prior to ICPI                                 ICPI details                                                        Initial best response to ICPI   Site of repeat biopsy showing SCLC                Genomic profile of SCLC                                                                                                                                                                          Treatment for SCLC                                                                    Site of PD of SCLC   Patient outcome post-SCLC dx
                                                                                                     neuroendocrine features on initial bx                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ----------------------------------------------- --------------------- ---------------------------- -------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------- ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- -------------------- ------------------------------------------------------
  Index case                                      Mid-60s F             Smoker\                      Poorly diff squamous/\                       ***TP53* mut (R283fs\*62** and G325), ***CDKN2A* R58 mut**,\                                       CBDCA/GEM\                                                       Nivo q2wk\                                                          PR                              Lung and level 7 and 4R mediastinal lymph nodes   ***TP53* R283fs\*62 mut**, ***CDKN2A* R58 mut**,\                                                                                                                                                CBDCA/VP16\                                                                           Systemic             Died 14 mo post SCLC dx
                                                                        (35 pack-years)              no                                           ***SOX2* amp**, ***PIK3CA* amp**, *ERBB4* amp, *REL* amp, *KRAS* amp, *ZNF703* amp, *FGFR*1 amp\   (4 cycles)                                                       (second line, 47 cycles)                                                                                                                              **SOX2 amp**, ***PIK3CA* amp**, *PIK3CA* E545K, *CCND2* amp, *CCND3* amp, *MYCL1* amp, *CSF3R* amp, *FGF23* amp, *FGF6* amp, *C17orf39* amp, *KDM5A* amp, *PRKCI* amp, *TERC* amp, *VEGF* amp\   (1st line, 4 cycles) -\> 8 month no therapy holiday                                                        
                                                                                                                                                  (Foundation Medicine)                                                                                                                                                                                                                                                                                                     (FoundationOne CDx)                                                                                                                                                                                                                                                                                         

  Nivo q4wk (3 cycles) + XRT to chest\            Systemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  (2nd line)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Iams *et al* [@R6]                              75 F                  Smoker\                      Adeno/\                                      ***KRAS* G12C mut**                                                                                CBDCA/PEM/BEV\                                                   Nivo q2wk\                                                          SD                              Station 7 mediastinal lymph node                  ***KRAS* G12C mut**, *TP53* R273C mut                                                                                                                                                            CBDCA/VP16\                                                                           Not specified        Died 16 mo post SCLC dx
                                                                        (30 pack-years)              not specified                                                                                                                                   (6 cycles) -\> maint. PEM/BEV \> 16 mo therapy holiday           (2nd line, 33 cycles) -\> 11 mo therapy holiday                                                                                                                                                                                                                                                                                                        (1st line, 4 cycles) -\> 4 mo therapy holiday                                                              

  Nivo/Ipi\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  (2nd line, 3 cycles)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Irinotecan\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  (3rd line, 10 cycles)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Iams *et al* [@R6]                              67 F                  Smoker\                      Adeno/\                                      *KRAS* G12C mut                                                                                    CBDCA/PTX\                                                       Nivo q2wk\                                                          Response                        Pericardial and pleural effusion                  *TP53* S315S frameshift mut,\                                                                                                                                                                    CBDCA/VP16 (1st line, 6 cycles) -\> 2 mo therapy holiday                              Not specified        Died 11 mo post SCLC dx
                                                                        (50 pack-years)              not specified                                                                                                                                   (4 cycles) -\> 17 mo therapy holiday                             (2nd line, 36 cycles)                                                                                                                                 *RB1* splice site mut                                                                                                                                                                                                                                                                                       

  PTX\                                            CNS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  (2nd line, 8 cycles)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Bar *et al* [@R7]                               70 F                  Active Smoker                Squamous/\                                   ***TP53* mut**\                                                                                    Palliative XRT to D5 vertebral lesion -\> CBDCA/GEM\             Nivo q2wk\                                                          PseudoPD                        Adrenal gland                                     ***TP53* mut**\                                                                                                                                                                                  Continued nivo for 2 mo - stopped 2/2 pneumonitis -\> 5 mo systemic therapy holiday   NA                   Alive 9 mo post SCLC dx; then lost to follow-up
                                                                                                     yes                                          (**Arg249Ser and Arg196Ter**)                                                                      (1st line, 5 cycles)                                             (2nd line, 3 cycles);\                                                                                                                                (**Arg249Ser and Arg196Ter**)                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                      (5th line, 10 mo)                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Single dose XRT to left lung hilum (3rd line)   Left adrenalectomy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Trial NCT02052492\* (4th line, 3--4 mo)         Re-started nivo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Bar *et al* [@R7]                               75 M                  Past Smoker\                 Squamous/\                                   *TP53* mut (Asn131fs and Pro177Ser), *FBXW7* Arg441Phe mut                                         Palliative XRT to mediastinal lesion -\> CBDCA/GEM\              Nivo\                                                               PR                              Lung                                              *TP53* Cys238Phe mut                                                                                                                                                                             CBDCA/VP16 -\> XRT to chest (1st line, 3--4 mo) -\> 2 mo therapy holiday              Systemic             Died 13 mo post SCLC dx
                                                                        (\>10 pack-years)            yes                                                                                                                                             (5 mo) -\> 3 mo therapy holiday                                  (2nd line, 6 mo); stopped 2/2 pneumonitis -\>2 mo therapy holiday                                                                                                                                                                                                                                                                                                                                                                                                 

  Nivo\                                           Systemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  (2nd line, 2 mo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  DTX\                                            NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  (3rd line, 1 mo), stopped 2/2 toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Gefitinib\                                      Not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  (4th line, 1 mo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Abdallah *et al* [@R8]                          65 M                  Smoker\                      Adeno/\                                      Negative for *EGFR*/*Alk* alterations                                                              CBDCA/PEM (6 cycles) -\> maint. PEM (9 cycles)                   Nivo\                                                               PD                              Lung                                              Not described                                                                                                                                                                                    CBDCA/VP16\                                                                           NA                   Response to chemotherapy
                                                                        (35 pack-years)              limited specimen                                                                                                                                                                                                 (2nd line,\                                                                                                                                                                                                                                                                                                                                            (2 cycles at the time of report)                                                                           
                                                                                                                                                                                                                                                                                                                      5 cycles)                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Abdallah *et al* [@R8]                          68 M                  Not described                Two primaries (Squamous and poorly diff)/\   Not described                                                                                                                                                       Pembro/CBDCA/PTX\                                                   PR                              Right hilar lymph node                            Not described                                                                                                                                                                                    CBDCA/VP16\                                                                           NA                   Alive with no evidence of disease 18 mo post SCLC dx
                                                                                                     limited specimen                                                                                                                                                                                                 (4 cycles) -\> maint. Pembro (26 cycles)                                                                                                                                                                                                                                                                                                               (4 cycles) -\> definitive XRT to chest                                                                     

  Imakita *et al* [@R9]                           75 M                  Smoker\                      Poorly diff/\                                Negative for *EGFR*/*Alk* alterations                                                              DTX/BEV (2--3 cycles) -\> 2--3 mo therapy holiday 2/2 toxicity   Nivo\                                                               PD                              Pleural fluid and subcutaneous tumor of chest     Not described                                                                                                                                                                                    Amrubicin                                                                             Systemic             Died 2 mo post-SCLC dx
                                                                        (50 pack-years)              no                                                                                                                                                                                                               (2nd line,\                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                      3 cycles)                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Okeya *et al* [@R10]                            66 M                  Smoker (45 pack-years)       Adeno/\                                      Indeterminate for *EGFR* mut, Negative for *Alk* alterations                                       CBDCA/PEM/BEV (4 cycles) -\> maint. PEM/BEV (2 cycles)           Pembro (2nd line, 2 cycles, 5 weeks)                                HyperPD                         Pleural fluid                                     Not described                                                                                                                                                                                    CBDCA/VP16 (1st line, 3 cycles)                                                       Not specified        Died 5 mo post SCLC dx
                                                                                                     limited specimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Amrubicin (2^nd^ line, 3 cycles)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bold red font represents shared genomic alterations in initial NSCLC and transformed SCLC.

\*NCT02052492 = single arm phase I clinical trial of vitamin D binding protein macrophage activator as immunotherapy.

-\>, followed by; 2/2, secondary to; adeno, adenocarcinoma; amp, amplification; BEV, bevacizumab; bx, biopsy; CBDCA, Carboplatin; CNS, central nervous system; diff, differentiated; DTX, Docetaxel; dx, diagnosis; EGFR, epidermal growth factor receptor; F, female; GEM, gemcitabine; ICPI, immune checkpoint inhibitor; Ipi, Ipilimumab; M, Male; maint., maintenance; mo, months; mut, mutation; NA, not applicable; Nivo, nivolumab; NSCLC, non-small cell lung cancer; PD, progressive disease; PEM, pemetrexed; Pembro, pembrolizumab; PR, partial response; PTX, paclitaxel; SCLC, small cell lung cancer; SD, stable disease; VP16, Etoposide; XRT, Radiotherapy.

Systematic review {#s3}
=================

We performed a systematic review of the literature, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, to identify similar published reports of NSCLC-to-small cell transformation on ICPIs ([figure 2](#F2){ref-type="fig"}). We searched PubMed, Embase and the American Society of Clinical Oncology/International Association for the Study of Lung Cancer virtual meeting library databases on 7 December 2019, using the keywords small cell transformation/neuroendocrine transformation with or without ICPIs/anti-PD-1/pembrolizumab/nivolumab/atezolizumab/durvalumab. Two investigators (KS and AV) independently reviewed abstracts and full-text articles. Patients with advanced NSCLC who had received molecularly targeted therapies prior to small cell transformation or non-lung primary cancers were excluded. Nine patients were identified from five articles (three case series[@R6] and two case reports[@R9]) and one meeting abstract (index case).

![PRISMA diagram detailing selection of published reports of mall cell transformation of non-small cell lung cancer with immune checkpoint inhibitors. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.](jitc-2020-000697f02){#F2}

All patients were on treatment with ICPIs at the time of detection of SCLC, with seven (77.8%) on nivolumab and two (22.22%) on pembrolizumab monotherapy. Five (55.6%) were male; median age was 68 years (range 65--75 years). All eight (100%) patients for whom smoking history was described had history of tobacco exposure. The median number of treatments received before ICPI was 1 (range 0--3). All (100%) patients had received chemotherapy before switch to either second line or maintenance ICPI. After detection of small cell transformation, seven (77.8%) patients received carboplatin/etoposide as the next immediate line of therapy. Among eight patients for whom survival data was available, median survival since detection of small cell transformation was 13.0 months (95% CI 2.0 to 16.0 months; Stata/IC V.15.1), which was comparable to 10.9 months (95% CI 8.0 to 13.7 months) previously reported with transformed *EGFR*-mutant lung adenocarcinoma on TKIs.[@R11] The full clinicopathological and tumor genomic details of these cases are summarized in [table 1](#T1){ref-type="table"}.

Discussion and conclusions {#s4}
==========================

No consensus guidelines exist on how to define NSCLC-to-small cell transformation and distinguish it from new primary SCLC. Absence of neuroendocrine features on initial biopsy, protracted response to nivolumab monotherapy and the near-identical genomic profile of the two tumors favored the diagnosis of histological transformation in our patient. Proof of transformation with molecular fingerprinting was described in only two of the other eight patients ([table 1](#T1){ref-type="table"}). The genomic profiles of 'transformed small cell tumors' in three patients were completely different from the 'original' NSCLC tumors, which raises the question of true treatment-induced transformation versus metachronous primary SCLC. Genomic profiling was not described in the remaining four cases. Presence of mixed small cell and non-small cell histology at diagnosis, minimum duration of therapy and attainment of initial response with ICPIs are other criteria which merit further investigation. Of note, two patients in [table 1](#T1){ref-type="table"} had received less than four cycles of ICPIs, while three patients did not have any on-treatment response.

The real-world frequency of histological transformation with ICPIs remains uncertain---and is likely under-recognized and under-reported due to the infrequency of tumor rebiopsy in advanced NSCLC being treated with sequential chemotherapies and/or ICPIs. Bar *et al* studied biopsies at the time of NSCLC progression on ICPIs at a single institution and reported a small cell transformation rate of 25% in 8 patients with NSCLC with available with preprogression and postprogression tissue biopsies (with two postprogression biopsies not showing any tumor cells).[@R7] However, Gettinger *et al* did not find any clear changes in lung cancer histology (0%) on evaluation of 23 NSCLC cases (all with tumor cells) from a single institution with acquired resistance to anti-PD-1 drugs.[@R12] Both studies are hampered by small sample sizes, which makes it prudent to study this putative phenomenon prospectively.

The underlying evolutionary genomic/epigenetic alterations responsible for this mechanism of therapeutic resistance warrant more detailed exploration. Insights from small cell transformation in *EGFR*-mutated lung adenocarcinoma and prostate adenocarcinoma may help direct further mechanistic investigations towards study of common cell-of-origin, drug-tolerant persister state and stromal interactions.[@R2] In the meanwhile, we recommend that tissue biopsies should be considered at the time of NSCLC progression on ICPIs similar to TKIs, if safe and feasible from the patient perspective.
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